Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 11;13(7):e0199745.
doi: 10.1371/journal.pone.0199745. eCollection 2018.

Disparities by race, age, and sex in the improvement of survival for lymphoma: Findings from a population-based study

Fahad Mukhtar  1 , Paolo Boffetta  2 , Bashir Dabo  1 , Jong Y Park  3 , Chi T D Tran  4 , Thuan V Tran  5   6 , Huong Thi-Thanh Tran  5   6 , Madison Whitney  1 , Harvey A Risch  7 , Linh C Le  8 , Wei Zheng  9 , Xiao-Ou Shu  9 , Hung N Luu  9   10   11
Affiliations

Disparities by race, age, and sex in the improvement of survival for lymphoma: Findings from a population-based study

Fahad Mukhtar et al. PLoS One. .

Abstract

Objective: To evaluate improvement in survival of lymphoma patients from 1990 to 2014, stratified by age, sex and race using Surveillance Epidemiology and End-Result Survey Program (SEER) data.

Study design and setting: We identified 113,788 incident lymphoma cases from nine SEER cancer registries were followed up for cause-specific mortality from lymphoma. Cox proportional hazard regression was used to estimate hazard ratios (HRs) and their respective 95% confidence interval (CIs) for various time periods within groups stratified by race, age and sex.

Results: Five-year survival for Hodgkin's lymphoma (HL) was 89% for patients 20-49 years of age. For this age group, compared to 1990-1994, survival significantly improved in 2000-2004 (HR = 0.65; 95% CI: 0.54-0.78), 2005-2009 (HR = 0.46, 95% CI: 0.38-0.57) and 2010-2014 (HR = 0.29, 95% CI: 0.20-0.41). Hodgkin's lymphoma patients aged 75-85 years had 5-year survival of 37% and in these patients, compared to 1990-1994, survival only improved from 2005 onward (HR = 0.67, 95% CI: 0.50-0.90). In patients with non-Hodgkin's Lymphoma (NHL), all age groups showed survival improvements between 1990-1994 period and 2010-2014 period. Improvements in HL and NHL survival were seen for all race categories and both genders.

Conclusion: Survival among US lymphoma patients has improved substantially between 1990-1994 period and 2010-2014 period, though disease-specific mortality was still higher in older age groups.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Forest plots showing Multivariate-Adjusted Hazard Ratios (HRs) and 95%CIs for cancer-specific death (due to lymphoma) by race and year of Diagnosis in 9 SEER Registries (1990–2014).
HL: Hodgkin’s Lymphoma; NHL: Non-Hodgkin’s Lymphoma; HR: Hazard ratio.
Fig 2
Fig 2. Forest plots showing Multivariate-Adjusted Hazard Ratios (HRs) and 95%CIs for Cancer-Specific Death (due to lymphoma), by Age Group and Year of Diagnosis in 9 SEER Registries (1990–2014).
HL: Hodgkin’s Lymphoma; NHL: Non-Hodgkin’s Lymphoma; HR: Hazard ratio.
Fig 3
Fig 3. Forest plots showing Multivariate-Adjusted Hazard Ratios (HRs) and 95% CIs for cancer-specific death (due to lymphoma) by stage and age group in 9 SEER Registries (1990–2014).
HL: Hodgkin’s Lymphoma; NHL: Non-Hodgkin’s Lymphoma; HR: Hazard ratio.
See this image and copyright information in PMC

References

    1. Wei W, Wu P, Li L, Zhang Z-H. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. Hematol Amst Neth. 2017;22: 320–329. doi: 10.1080/10245332.2016.1264163 - DOI - PubMed
    1. ‘t Mannetje A, De Roos AJ, Boffetta P, Vermeulen R, Benke G, Fritschi L, et al. Occupation and Risk of Non-Hodgkin Lymphoma and Its Subtypes: A Pooled Analysis from the InterLymph Consortium. Environ Health Perspect. 2016;124: 396–405. doi: 10.1289/ehp.1409294 - DOI - PMC - PubMed
    1. National Cancer Institute. Overview of the SEER Program [Internet]. National Cancer Institute; 2018. Available: http://seer.cancer.gov/about/
    1. Suneja G, Shiels MS, Angulo R, Copeland GE, Gonsalves L, Hakenewerth AM, et al. Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol. 2014;32: 2344–2350. doi: 10.1200/JCO.2013.54.8644 - DOI - PMC - PubMed
    1. Castel AD, Young H, Akiwumi A-M, Vargas A, Rogers K, West T, et al. Trends in cancer diagnoses and survival among persons with AIDS in a high HIV prevalence urban area. AIDS Care. 2015;27: 860–869. doi: 10.1080/09540121.2015.1011074 - DOI - PubMed

Publication types